Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17975213 | 0.76 | KMT2A (0.39) | MEN1KMT2AL3MBTL1ATMGPR35 | |
| SCHEMBL30367674 | 0.72 | NOTUM (0.42) | NOTUMGPR35GAA | |
| SCHEMBL16169594 | 0.68 | ATM (0.40) | MEN1KMT2AL3MBTL1ATMGPR35 | |
| SCHEMBL22729865 | 0.66 | ATM (0.37) | MEN1KMT2AL3MBTL1ATMNOTUM | |
| SCHEMBL70763 | 0.63 | KDM4E (0.46) | MEN1KMT2AL3MBTL1ATMNOTUM | |
| SCHEMBL25529107 | 0.63 | KMT2A (0.40) | MEN1KMT2AL3MBTL1ATMGPR35 | |
| SCHEMBL26967907 | 0.62 | KDM4E (0.42) | MEN1KMT2AL3MBTL1ATMNOTUM | |
| SCHEMBL17963309 | 0.61 | CYP1A2 (0.36) | MEN1KMT2AMAPTPKM | |
| SCHEMBL4585396 | 0.60 | NOTUM (0.61) | MEN1KMT2ANOTUMGPR35GAA | |
| SCHEMBL16460308 | 0.60 | ADORA2A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | TAF1, TAF1L, TAF1B | MEN1 1152/4885KMT2A 3169/4885L3MBTL1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.